Transitioning From Using RUO To cGMP Chemicals For Clinical Trials

New and emerging biopharma companies who want to be first to market with their molecule are feeling the pressure of balancing budgetary and regulatory requirements while accelerating the pace from lab to clinic. Learn about these common challenges and risks including the price of supply disruptions. In this article, you will also learn how to avoiding time-consuming and costly pitfalls such as non-conformances, sourcing, and manufacturing delays to maintaining momentum in the drug development process. Thermo Fisher Scientific emphasizes the importance of the right supply chain management partner.